Arete Therapeutics Names James Sabry, M.D., Ph.D., President and Chief
Executive Officer
HAYWARD, Calif., July 8 /PRNewswire/ -- Arete Therapeutics Inc., a
privately-held biopharmaceutical company developing first-in-class soluble
epoxide hydrolase (s-EH) inhibitors, today announced the appointment of James
Sabry, M.D., Ph.D., as president and chief executive officer. Dr. Sabry has
been a strategic advisor and member of the board of directors since March
2008. Dr. Sabry succeeds Dinesh Patel in the position of president and chief
executive officer, who will remain as a consultant to the company.
"James brings a wealth of drug discovery, development, and biotechnology
management expertise to Arete and already has made significant contributions
to the company. We are confident that his exceptional entrepreneurial
leadership will guide the company in the years to come as Arete continues to
advance its pipeline of innovative compounds through clinical development,"
said James Topper, M.D., Ph.D., chairman of the board of Arete Therapeutics
Inc. "In addition, on behalf of the board of directors, I would like to thank
Dinesh Patel for his dedication and commitment to building a successful
biotechnology organization while transitioning Arete from a discovery to a
clinical stage company."
Dr. Sabry is chairman of the board of directors and former CEO of
Cytokinetics, a company he co-founded in August 1997. Prior to co-founding
Cytokinetics, he held faculty positions at the University of California, San
Francisco and Harvard Medical School. He serves on the board of directors of
HopeLab, a not-for-profit organization developing innovative technologies for
the management of cancer, obesity and other diseases, is a member of Dean's
Council of the Kennedy School of Government at Harvard University and serves
on the advisory boards of numerous organizations including the California
Institute of Quantitative Biosciences. Dr. Sabry received an M.D. from Queen's
University and a Ph.D. in cell biology from the University of California, San
Francisco.
"Arete Therapeutics is uniquely positioned to develop its pipeline of
novel soluble epoxide hydrolase inhibitors for multiple disease indications
and I look forward to applying my experience to build on the strong foundation
and take the company to the next level of strategic and scientific
excellence," said Dr. Sabry.
About Arete Therapeutics Inc.
Arete Therapeutics Inc. is a privately-held pharmaceutical company
discovering and developing first-in-class small molecule drugs directed at
soluble epoxide hydrolase (s-EH), a unique enzyme which plays a key role in
the arachidonic acid pathway. Arete has discovered and developed a series of
proprietary and chemically diverse molecules with preclinical efficacy in
various animal models, and is conducting a phase 1 clinical trial with its
first-in-class compound, AR9281. The company has raised a total of $51 million
in Series A financing led by Frazier Healthcare Ventures, Alta Partners, Three
Arch Partners, Burrill & Company and Altitude Life Science Ventures. For more
information on Arete Therapeutics, please visit
http://www.aretetherapeutics.com.
SOURCE Arete Therapeutics Inc.
Angela Bitting, +1-925-202-6211, a.bitting@comcast.net, for Arete
Therapeutics
